Key result
Transfemoral TAVR was associated with higher 5-year mortality than SAVR in propensity-matched patients with severe aortic stenosis at low and intermediate risk.
Why the study?
Although 1-year mortality was similar after transfemoral TAVR and SAVR in real-world propensity-matched patients at low and intermediate risk, 5-year outcomes remained to be evaluated.
Does transfemoral TAVR compared to SAVR improve 5-year mortality and major adverse cardiac and cerebrovascular events in real-world patients with severe aortic stenosis at low and intermediate risk?
Observational (n=1,300)
Does transfemoral TAVR compared to SAVR improve 5-year mortality and major adverse cardiac and cerebrovascular events in real-world patients with severe aortic stenosis at low and intermediate risk?
In a real-world, propensity-matched cohort of low- and intermediate-risk patients with severe aortic stenosis, SAVR was associated with lower 5-year mortality and MACCE compared to first-generation transfemoral TAVR.
Answers are grounded in this paper and cite their sources.
Caution advised with transfemoral TAVR in low- and intermediate-risk patients; leaves open need for randomized long-term confirmation.
BACKGROUND: The OBSERVANT study (Observational Study of Effectiveness of SAVR-TAVI Procedures for Severe Aortic Stenosis Treatment) showed that mortality at 1 year is similar after transfemoral transcatheter aortic valve replacement (TAVR) or surgical aortic valve replacement (SAVR) for real-world propensity-matched patients with aortic stenosis at low and intermediate risk. We report the 5-year outcomes of the Italian OBSERVANT study. METHODS AND RESULTS: The unadjusted enrolled population (N=7618) between December 2010 and June 2012 included 5707 patients on SAVR and 1911 patients on TAVR. The propensity score method was applied to select 2 groups with similar baseline characteristics. All outcomes were adjudicated through a linkage with administrative databases. The primary end points of this analysis were death from any cause and major adverse cardiac and cerebrovascular events at 5 years. The matched population had a total of 1300 patients (650 per group). The propensity score method generated a low and intermediate-risk population (mean logistic EuroSCORE 2: 5.1±6.2% versus 4.9±5.1%, SAVR versus transfemoral TAVR; P=0.485). At 5 years, the rate of 5 death from any cause was 35.8% in the surgical group and 48.3% in the transcatheter group (hazard ratio, 1.38; 95% CI, 1.12-1.69; P=0.002). Similarly, TAVR was associated with an increased risk of major adverse cardiac and cerebrovascular events as compared with SAVR (42.5% versus 54.0%; hazard ratio, 1.35; 95% CI, 1.11-1.63; P=0.003). The cumulative incidence of cerebrovascular events, myocardial infarction, and coronary revascularization were similar in the study groups at 5 years. CONCLUSIONS: The present results suggest that at 5 years, in a real-world population with severe aortic stenosis and at low and intermediate risk, suggest that SAVR is associated in with lower mortality and major adverse cardiac and cerebrovascular events rates than transfemoral TAVR performed using first-generation devices. These data need to be confirmed in randomized trials using new-generation TAVR devices.
No takes yet. Share an insight, caveat, or question.
Barbanti et al. (2019) conducted an observational in severe aortic stenosis (n=1,300). Transfemoral transcatheter aortic valve replacement (TAVR) vs. Surgical aortic valve replacement (SAVR) was evaluated on death from any cause (HR 1.38, 95% CI 1.12-1.69, p=0.002). Transfemoral TAVR was associated with higher 5-year mortality than SAVR in propensity-matched patients with severe aortic stenosis at low and intermediate risk.
Synapse has enriched 10 related papers. Consider them for comparative context: